See more : Hypothekarbank Lenzburg AG (0QLK.L) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Tian Lun Gas Holdings Limited (1600.HK) Income Statement Analysis – Financial Results
- Metro Pacific Investments Corporation (MPCFF) Income Statement Analysis – Financial Results
- FTAC Parnassus Acquisition Corp. (FTPAU) Income Statement Analysis – Financial Results
- Econocom Group SE (ECONB.BR) Income Statement Analysis – Financial Results
- TalkPool AG (TALK.ST) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
New Study Highlights Importance of Testing for Aspirin Effect with FDA-Cleared AspirinWorks® Test
DENVER--(BUSINESS WIRE)--By failing to address the most common causes of aspirin ineffectiveness, a small clinical study recently published online in the journal Circulation highlights the importance of clinically validated, FDA-cleared testing for aspirin effect with the AspirinWorks® Test to help...
Corgenix and Viral Hemorrhagic Fever Consortium Release New Findings from Sierra Leone Lassa Virus Program
ATLANTA & DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits and the Viral Hemorrhagic Fever Consortium (VHFC) released new scientific data resulting from the consortium’s ongoing studies at the Kenema Government Hospital...
Corgenix Reports First Quarter Fiscal 2013 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company achieved record operating results for the quarter...
Corgenix Receives Regulatory Approval for Sale of AspirinWorks® in China
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today that the Company’s AspirinWorks® ELISA product has received notification of regulatory approval from the State Food and Drug Administration (SFDA) of the...
Corgenix to Host Conference Call to Discuss First Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Tuesday, November 13, 2012, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its...
Corgenix Reports Fiscal 2012 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results. The report disclosed that the Company’s operating results have advanced for the fiscal...
Corgenix to Host Conference Call to Discuss Fiscal 2012 Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, September 27, 2012, at 4:00 PM EDT to discuss the company’s financial and operating performance for its...
Corgenix Updated Revenue Guidance for FY 2012 Financials
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported that preliminary revenue results continued strong in the fourth quarter (ended June 30, 2012), coming in at approximately $2,328,000. Given the preliminary...
Corgenix Announces Manufacturing, Supply Agreement with diaDexus
DENVER & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC: CONX.OB) (“Corgenix Medical”), a worldwide developer and marketer of diagnostic test kits, today announced that its wholly owned subsidiary, Corgenix, Inc. (Corgenix, Inc., together with Corgenix Medical, are herein referred...
Corgenix Announces Issuance of Additional U.S. Patent for AspirinWorks® (11-dehydro Thromboxane B2) Test
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks® technology. The U.S. Patent and Trademark Office has issued U.S. Patent No. 8,168,400 on the...
Source: https://incomestatements.info
Category: Stock Reports